Business
Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America
New data link beneficial microbiome changes in Ph2a CDI patients to earlier results from Ph1 healthy volunteers to predict potential anti-recurrence
About this update from Acurx Pharmaceuticals, Inc.
[{"type":"text","content":"New data link beneficial microbiome changes in Ph2a CDI patients to earlier results from Ph1 healthy volunteers to predict potential anti-recurrence properties of ibezapolstatNew in vitro data show ibezapolstat is effective against high bacterial concentration (inoculum) of C. difficile) and does not induce production of C. difficile toxins A or BSTATEN ISLAND, N.Y., Aug. 2, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (\"Acurx\" or the \"Company\"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that new microbiome data from its Phase 2a clinical trial (completed in 4Q 2020) in patients with C. difficile Infection (CDI), as well as new in vitro microbiology results generated in 2Q 2022, in each case, were presented at the 16th Biennial Congress of the Anaerobe Society of America.\nAn oral presentation was made on July 30, 2022, during Session VIII on Clostridioides difficile Management Update by Dr. Kevin Garey, Professor and Chair, University of Houston College of Pharmacy and the Principal Investigator for microbiome aspects of the ibezapolstat clinical trial program. According to Dr. Garey, \"The overall exceptional clinical trial results reported to date in CDI patients and in healthy volunteers show ibezapolstat to have ideal pharmacokinetic characteristics of high fecal concentrations with minimal systemic exposure- a likely reason for this novel drug to be well-tolerated in patients.\" He further stated: \"Ibezapolstat demonstrated beneficial effects on the gut microbiome of CDI patients consistent with similar data from healthy volunteers, including increasing alpha diversity while on therapy; an increased proportion of Firmicutes with Clostridiales being the most common taxa; and a dramatic favorable effect on bile acids. The added value of an active comparator (vancomycin) control group in the preceding Phase 1 trial is a pioneering approach which we believe can become the new paradigm for early-phase CDI drug development. Together with the highly selective effects on the gut microbiome metagenomics analyses, favorable changes in gut bile acid metabolism provide strong rationale for prediction of ibezapolstat microbiome changes that protect against recurrent CDI.\"\nIn addition, a scientific poster was pre...